{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:15:22Z","timestamp":1740107722872,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10067-021-05840-2","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T06:39:12Z","timestamp":1632811152000},"page":"45-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Perceptions and behaviours related to COVID-19 in patients with rheumatoid arthritis: a cross-sectional study"],"prefix":"10.1007","volume":"41","author":[{"given":"Takahiro","family":"Itaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mie","family":"Torii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-060X","authenticated-orcid":false,"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Jindai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyosuke","family":"Tanigawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Urai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayae","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Nin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Morinobu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"5840_CR1","doi-asserted-by":"publisher","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79(7):859\u201366. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217871","DOI":"10.1136\/annrheumdis-2020-217871"},{"key":"5840_CR2","doi-asserted-by":"publisher","unstructured":"Ye C, Cai S, Shen G, et al (2020) Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. Ann Rheum Dis 79(8):1007\u201313. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217627","DOI":"10.1136\/annrheumdis-2020-217627"},{"key":"5840_CR3","doi-asserted-by":"publisher","unstructured":"Della-Torre E, Campochiaro C, Cavalli G, et al (2020) Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis 79(10):1277\u201385. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218122","DOI":"10.1136\/annrheumdis-2020-218122"},{"key":"5840_CR4","doi-asserted-by":"publisher","unstructured":"Gupta S, Wang W, Hayek SS, et al (2020) Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med https:\/\/doi.org\/10.1001\/jamainternmed.2020.6252","DOI":"10.1001\/jamainternmed.2020.6252"},{"key":"5840_CR5","doi-asserted-by":"publisher","unstructured":"Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 52(1):53\u201361. https:\/\/doi.org\/10.1093\/rheumatology\/kes305","DOI":"10.1093\/rheumatology\/kes305"},{"key":"5840_CR6","doi-asserted-by":"publisher","unstructured":"Wolf MS, Serper M, Opsasnick L, et al (2020) Awareness, attitudes, and actions related to COVID-19 among adults with chronic conditions at the onset of the U.S. outbreak: a cross-sectional survey. Ann Intern Med 173(2):100\u20139.\u00a0https:\/\/doi.org\/10.7326\/m20-1239","DOI":"10.7326\/m20-1239"},{"key":"5840_CR7","doi-asserted-by":"publisher","unstructured":"McCaffery KJ, Dodd RH, Cvejic E, et al (2020) Health literacy and disparities in COVID-19-related knowledge, attitudes, beliefs and behaviours in Australia. Public Health Res Pract 30(4):e30342012. https:\/\/doi.org\/10.17061\/phrp30342012","DOI":"10.17061\/phrp30342012"},{"key":"5840_CR8","doi-asserted-by":"publisher","unstructured":"Terao C, Hashimoto M, Yamamoto K, et al (2013) Three groups in the 28 joints for rheumatoid arthritis synovitis\u2013analysis using more than 17,000 assessments in the KURAMA database. PloS One 8(3):e59341.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0059341","DOI":"10.1371\/journal.pone.0059341"},{"key":"5840_CR9","doi-asserted-by":"publisher","unstructured":"Arnett FC, Edworthy SM, Bloch DA, et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315\u201324. https:\/\/doi.org\/10.1002\/art.1780310302","DOI":"10.1002\/art.1780310302"},{"key":"5840_CR10","doi-asserted-by":"publisher","unstructured":"Aletaha D, Neogi T, Silman AJ, et al. (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569\u201381. https:\/\/doi.org\/10.1002\/art.27584","DOI":"10.1002\/art.27584"},{"key":"5840_CR11","doi-asserted-by":"publisher","unstructured":"Kelly B, Squiers L, Bann C, et al (2015) Perceptions and plans for prevention of Ebola: results from a national survey. BMC Public Health 15(1):1136. https:\/\/doi.org\/10.1186\/s12889-015-2441-7","DOI":"10.1186\/s12889-015-2441-7"},{"key":"5840_CR12","doi-asserted-by":"publisher","unstructured":"Suka M, Odajima T, Kasai M, et al (2013) The 14-item health literacy scale for Japanese adults (HLS-14). Environ Health Prev Med 18(5):407\u201315. https:\/\/doi.org\/10.1007\/s12199-013-0340-z","DOI":"10.1007\/s12199-013-0340-z"},{"key":"5840_CR13","doi-asserted-by":"publisher","unstructured":"Mehta B, Jannat-Khah D, Fontana MA, et al (2020) Impact of COVID-19 on vulnerable patients with rheumatic disease: results of a worldwide survey. RMD Open 6(3):e001378. https:\/\/doi.org\/10.1136\/rmdopen-2020-001378","DOI":"10.1136\/rmdopen-2020-001378"},{"key":"5840_CR14","doi-asserted-by":"publisher","unstructured":"Zheng Z, Peng F, Xu B, et al (2020) Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect 81(2):e16\u2013e25. https:\/\/doi.org\/10.1016\/j.jinf.2020.04.021","DOI":"10.1016\/j.jinf.2020.04.021"},{"key":"5840_CR15","doi-asserted-by":"publisher","unstructured":"Banerjee A, Pasea L, Harris S, et al (2020) Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. Lancet (London, England) https:\/\/doi.org\/10.1016\/s0140-6736(20)30854-0","DOI":"10.1016\/s0140-6736(20)30854-0"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05840-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05840-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05840-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T05:24:33Z","timestamp":1641273873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05840-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["5840"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05840-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"assertion":[{"value":"10 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethical Review Board at Kyoto University Graduate School and Faculty of Medicine Kyoto University Hospital Ethics Committee, Kyoto, Japan, approved the study (approval number: R0357).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participation and publication"}},{"value":"Department of Advanced Medicine for Rheumatic Diseases is supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan and five pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd, UCB Japan Co. Ltd, AYUMI Pharmaceutical Co. and Asahi Kasei Pharma Corp.). MH received a research grant and\/or speaker fee from Bristol-Myers, Eisai, Eli Lilly and Mitsubishi Tanabe Pharma. RW received speaker\u2019s fee from Mitsubishi Tanabe Pharma, Pfizer, Sanofi, AbbVie, Asahi Kasei, Eisai, Eli Lilly, Bristol-Myers Squibb and Janssen. KMurat received speaker fees from Eisai Co., Ltd. MTa received research grants and\/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Corp., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Pfizer Inc., UCB Japan Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K., Taisho Pharma Co., Ltd., Takeda Pharmaceutical Co.,\u00a0Ltd. HI received research grants and\/or speaker fees from BMS, Kyocera, Asahi-Kasei, Eisai, Mochida and Toyama. SM received research grants and\/or speaker fees from AYUMI Pharmaceutical Co., Pfizer Inc., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Kyocera, Chugai Pharmaceutical Co. Ltd., Mochida and Taisho Pharma Co., Ltd. AM received speaking fees and\/or research grants from Eli Lilly Japan K.K., Ono Pharmaceutical Co., Pfizer Inc., UCB Japan, AbbVie G.K., Asahi Kasei Pharma and Chugai Pharmaceutical Co. Ltd. TI, MTo, WY, KT, YU, AK, KN, KJ and KMurak have declared no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}